Organon & Co. financial data

Symbol
OGN on NYSE
Industry
Pharmaceutical Preparations
Location
30 Hudson Street, Fl 33, Jersey City, NJ
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 28, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 165 % +2.55%
Quick Ratio 48.6 % +2.27%
Debt-to-equity 4.21K %
Return On Equity 299 %
Return On Assets 6.93 % -24.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 258M shares +0.3%
Common Stock, Shares, Outstanding 258M shares +0.85%
Entity Public Float 5.3B USD 0%
Common Stock, Value, Issued 3M USD 0%
Weighted Average Number of Shares Outstanding, Basic 257M shares +0.71%
Weighted Average Number of Shares Outstanding, Diluted 259M shares +1.13%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 6.4B USD +2.24%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 807M USD +19.9%
Income Tax Expense (Benefit) -57M USD +83.7%
Net Income (Loss) Attributable to Parent 864M USD -15.5%
Earnings Per Share, Basic 3.36 USD/shares -16.2%
Earnings Per Share, Diluted 3.33 USD/shares -16.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 675M USD -2.6%
Accounts Receivable, after Allowance for Credit Loss, Current 1.36B USD -22.1%
Inventory, Net 1.32B USD +0.46%
Other Assets, Current 994M USD +31.5%
Assets, Current 4.35B USD -3.55%
Property, Plant and Equipment, Net 1.17B USD -1.27%
Operating Lease, Right-of-Use Asset 157M USD -9.25%
Goodwill 4.68B USD +1.67%
Assets 13.1B USD +8.65%
Accounts Payable, Current 1.15B USD -12.3%
Liabilities, Current 2.72B USD -6.85%
Deferred Income Tax Liabilities, Net 74M USD +57.4%
Operating Lease, Liability, Noncurrent 112M USD -10.4%
Other Liabilities, Noncurrent 977M USD +137%
Liabilities 12.6B USD +4.13%
Accumulated Other Comprehensive Income (Loss), Net of Tax -649M USD -20%
Retained Earnings (Accumulated Deficit) 1.01B USD +128%
Stockholders' Equity Attributable to Parent 472M USD
Liabilities and Equity 13.1B USD +8.65%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 76M USD -33.3%
Net Cash Provided by (Used in) Financing Activities -74M USD +77.3%
Net Cash Provided by (Used in) Investing Activities -96M USD -77.8%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 258M shares +0.85%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -118M USD +52.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 675M USD -2.6%
Deferred Tax Assets, Valuation Allowance 261M USD -15.5%
Deferred Tax Assets, Gross 1.3B USD +10.7%
Operating Lease, Liability 156M USD -8.77%
Depreciation 32M USD +14.3%
Payments to Acquire Property, Plant, and Equipment 46M USD 0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 756M USD -27.7%
Lessee, Operating Lease, Liability, to be Paid 177M USD -6.35%
Operating Lease, Liability, Current 44M USD -4.35%
Lessee, Operating Lease, Liability, to be Paid, Year Two 34M USD -29.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 49M USD -5.77%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Deferred Income Tax Expense (Benefit) 5M USD +66.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 21M USD +16.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 28M USD -3.45%
Deferred Tax Assets, Operating Loss Carryforwards 224M USD +540%
Unrecognized Tax Benefits 121M USD +5.22%
Lessee, Operating Lease, Liability, to be Paid, Year Four 18M USD +28.6%
Deferred Tax Assets, Net of Valuation Allowance 1.04B USD +20%
Share-based Payment Arrangement, Expense 105M USD +3.96%
Interest Expense 520M USD -1.33%